Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis.

Carlo Pozzilli1, Giovanni Antonini, Francesca Bagnato

  • 1Department of Neurological Sciences, University La Sapienza, Rome, Italy. carlo.pozzilli@uniroma1.it

Journal of Neurology
|April 17, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Targeting shared immune pathways in multiple sclerosis and type 1 diabetes: Therapeutic insights from monoclonal antibodies.

Autoimmunity reviews·2026
Same author

Spinal cord imaging for multiple sclerosis: Advances, priorities, and opportunities.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability.

Neurology·2026
Same author

Clinical, structural, and functional MRI features predicting PIRMA at 5-year follow-up in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Generalizable spinal cord multiple sclerosis lesion segmentation across MRI contrasts, protocols, and centers.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Correction: Long-term neurological outcome after hematopoietic stem cell transplant in juvenile Krabbe disease.

Journal of neurology·2026
Same journal

Radiological and FDG-PET imaging features of Epstein-Barr virus-positive primary central nervous system lymphomas.

Journal of neurology·2026
Same journal

Unexpected widespread amyloid PET positivity in a patient with CADASIL.

Journal of neurology·2026
Same journal

Movement disorders in GLUT1 deficiency syndrome: a systematic review of the literature.

Journal of neurology·2026
Same journal

Detailed clinical characteristics of musical hallucinations in 81 patients.

Journal of neurology·2026
Same journal

The dual role of mTOR in multiple sclerosis pathophysiology: a systematic review.

Journal of neurology·2026
See all related articles
This summary is machine-generated.

Neutralizing antibodies to interferon beta (IFNbeta) can reduce treatment effectiveness in multiple sclerosis (MS) patients. Combining IFNbeta-1b with methylprednisolone significantly reduces the occurrence of these antibodies during the first year of therapy.

Area of Science:

  • Neuroimmunology
  • Pharmacology
  • Clinical Therapeutics

Background:

  • Neutralizing antibodies (NAB) to interferon beta (IFNbeta) can develop in multiple sclerosis (MS) patients.
  • The presence of NAB may diminish the therapeutic efficacy of IFNbeta treatments.
  • Understanding factors influencing NAB formation is crucial for optimizing MS management.

Purpose of the Study:

  • To compare the frequency of NAB occurrence in MS patients treated with IFNbeta-1b alone versus IFNbeta-1b combined with monthly intravenous methylprednisolone (MP).

Main Methods:

  • 161 relapsing-remitting MS patients were randomized into two groups: IFNbeta-1b alone or IFNbeta-1b plus monthly MP.
  • NAB levels were assessed using the MxA assay at baseline and various follow-up points up to 15 months.
  • NAB positivity was defined using two criteria: one or more non-consecutive positive samples, or at least two consecutive positive samples.

Related Experiment Videos

Main Results:

  • NAB (definition I) occurred in 26.8% of patients on IFNbeta-1b alone versus 12.1% in the combination arm (p=0.05).
  • Using definition II, NAB rates were 22.5% (IFNbeta-1b alone) and 10.6% (combination), with a relative reduction of 52.9% (p=0.10).
  • Patients receiving combination therapy had a significantly higher probability of remaining NAB-free (p=0.031 for definition I, p=0.049 for definition II).

Conclusions:

  • Monthly pulses of intravenous methylprednisolone combined with IFNbeta-1b reduce the incidence of neutralizing antibodies to IFNbeta in MS patients.
  • This combination therapy appears to mitigate a key factor associated with reduced treatment response in MS.
  • The findings suggest a potential benefit of combination therapy in maintaining long-term treatment efficacy for MS.